IceCure’s FDA-cleared cryoablation system for breast cancer is gaining physician and patient traction, sending shares up more than 200% on heavy volume.
Investorideas.com (www.investorideas.com) a go-to platform for big investing ideas, including biotech and medical tech stocks issues a news and trading alert for IceCure Medical Ltd. (NASDAQ: ICCM),
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense(R) system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia
The stock is on the Nasdaq top gainers list today following news , currently trading at 6.55 +4.42 (+207.51%) on volume of 104 Million shares as of this report.
Advertisement
IceCure Medical today reported a 70% increase in its U.S. active commercial install base of ProSense(R) for breast cancer cryoablation following U.S. Food and Drug Administration (FDA) marketing authorization in October 2025, reflecting accelerating commercial adoption, expanding physician demand and continued growth in the Company’s U.S. footprint.
IceCure develops and commercializes its minimally invasive cryoablation technology that destroys tumors by freezing, offering an option to surgical tumor removal for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgery.
IceCure has continued to add new ProSense(R) systems to its installment base at clinics and hospitals across the U.S. As adoption expands, ProSense(R) breast cancer cryoablation procedures have been performed in major metropolitan areas throughout the country, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis and many other communities.
The Company had strong engagement at two of the leading breast health conferences held this earlier year, the Society of Breast Imaging (“SBI”) Annual Symposium and the American Society of Breast Surgeons (“ASBrS”) Annual Meeting, where IceCure generated significantly more sales leads for ProSense(R) systems compared to the same events in 2025, prior to FDA authorization, reflecting significantly increased interest from physicians and healthcare providers.
“With growing physician interest, expanding clinical acceptance, and increased patient awareness, we believe we remain in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S.,” said IceCure’s Chief Executive Officer, Eyal Shamir. “We are focused on continuing to expand our installed base, supporting physicians with training and education and increasing access to ProSense(R) for eligible patients.”
In addition to regulatory approval, other factors driving demand are:
Growing Clinical Acceptance – ASBrS recently updated its Resource Guide to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking an important milestone in the clinical adoption of minimally invasive breast cancer therapies. IceCure believes the updated guidance reflects growing recognition among breast surgeons and healthcare professionals of cryoablation’s potential role in treating appropriately selected patients.
Increasing Patient Awareness – Patient awareness of breast cancer cryoablation continues to grow as ProSense(R) receives broader media attention. Recent coverage by Reuters and local television news segments aired across approximately 190 CBS and CW-affiliated stations nationwide (including Boston, Philadelphia, and Chicago) have highlighted cryoablation as a minimally invasive alternative to surgery for eligible breast cancer patients. IceCure believes this increased visibility is helping educate patients and physicians about available treatment options.
Full news
https://money.tmx.com/quote/ICCM:US/news/5645603389770064/IceCure_Reports_70_Growth_in_Active_US_Commercial_Install_Base_for_Breast_Cancer_Cryoablation_Following_FDA_Clearance
Disclaimer / Disclosure: InvestorIdeas.com is a digital publisher of financial content and is not a registered investment adviser or broker-dealer. This article is informational and is not a recommendation to buy or sell any security; some content may be sponsored or compensated. See our full disclaimer.
